YSR3 Antibody

Basic Research Questions

• What are the key characteristics of antibodies targeting MAP3K15/ASK3?

  Anti-ASK3 antibodies (also known as MAP3K15 antibodies) enable detection and measurement of the ASK3 antigen in biological samples. The target protein functions in protein phosphorylation pathways and has a canonical amino acid length of 1313 residues with a molecular mass of 147.4 kilodaltons in humans . Three isoforms have been identified, and ASK3 belongs to the STE Ser/Thr protein kinase protein family . Applications for anti-ASK3 antibodies include Western blotting, ELISA, flow cytometry, and immunohistochemistry, with reactivity against human and mouse specimens .

  When selecting an antibody for ASK3 detection, researchers should consider the specific epitope region (e.g., N-terminal targeted antibodies) and validate reactivity against the species of interest. The antibody's performance in different applications should be experimentally confirmed before proceeding with larger studies.

• How do antibody variable regions contribute to immune function beyond antigen binding?

  Beyond traditional antigen binding, the variable regions of antibodies can directly influence innate immunity. Research demonstrates that synthetic peptides with sequences identical to VHCDR3 (third complementarity-determining region of the heavy chain variable domain) of certain monoclonal antibodies can be internalized by macrophages . This uptake stimulates proinflammatory cytokine production, activates the PI3K-Akt pathway, and upregulates TLR-4 expression .

  Notably, a study showed that a VHCDR3 peptide derived from a mouse monoclonal antibody specific for difucosyl human blood group A exerted therapeutic effects against systemic candidiasis without possessing direct candidacidal properties . This demonstrates how antibody variable regions can bridge adaptive and innate immunity, suggesting novel mechanisms for antibody-based therapeutics that extend beyond traditional neutralization or opsonization.

• What parameters should researchers consider when evaluating antibody validation data?

  When evaluating antibody validation data, researchers should consider multiple parameters that influence reliability:

  • Application-specific validation: An antibody performing well in Western blot may not necessarily work in immunohistochemistry or immunoprecipitation .

  • Target specificity: Confirm the antibody detects the intended protein by validating with knockout/knockdown controls or orthogonal methods .

  • Cross-reactivity assessment: Evaluate potential off-target binding, particularly for antibodies targeting protein families with conserved domains.

  • Reproducibility across batches: Verify consistency between different lots or production runs.

  • Experimental conditions: Consider buffer compositions, fixation methods, and incubation parameters that may affect binding efficacy.

  The YCharOS platform has evaluated approximately 1,000 antibodies directed at ~100 human protein targets, defining performance based on correct binding to target proteins in western blot, immunoprecipitation, and immunofluorescence experiments . This standardized characterization approach provides valuable data for researchers to make informed decisions about antibody selection.

Advanced Research Questions

• How does antibody repertoire analysis in autoimmune conditions reveal disease-specific patterns?

  Antibody repertoire analysis in autoimmune diseases has revealed distinctive patterns in variable gene usage, CDR3 characteristics, and somatic hypermutation. In systemic lupus erythematosus (SLE), multiple studies have identified consistent modifications in the antibody repertoire compared to healthy controls, as summarized in the following table:

  Reference	Sample Size	Key Findings
  Fraser et al. (2003)	1 SLE patient	Increased IGHV5 family usage; underrepresentation of IGHV1 family
  Arbuckle et al. (2003)	8 SLE patients	Increased IGHV4-34 usage; some antibody-secreting cells produced unmutated autoantibodies
  Tipton et al. (2015)	8 SLE patients, 8 controls	Increased IGHV4-34 in antibody-secreting cells; polyclonal expansions; lower somatic hypermutation in antibody-secreting cells
  Liu et al. (2017)	10 SLE, 6 healthy controls	Higher percentage of charged amino acids (especially arginine) in CDR3 regions compared to healthy controls

  These patterns suggest underlying mechanisms in B-cell selection and tolerance that contribute to autoimmunity. The increased usage of certain variable gene families (particularly IGHV4) and alterations in CDR3 composition may influence antigen recognition patterns and contribute to autoreactivity .

• What methodologies are being used to benchmark generative models for antibody design?

  Current methodologies for benchmarking generative models in antibody design employ diverse datasets with experimentally validated binding affinities. Researchers utilize:

  • Specialized antibody datasets: The Abbott dataset (422 HCDR3 sequences) and SPR control dataset containing binders with varying HCDR regions provide training and validation resources .

  • Target-specific mutation analysis: The Nature datasets published by Porebski et al. (2024) provide experimental results for three targets (HER2, HEL, and IL7), where:

    • HER2 dataset contains mutations solely in the HCDR3 region

    • IL7 dataset includes mutations in both LCDR1 and LCDR3 regions

    • HEL dataset features nanobodies with mutations across all three CDR regions

  • Structural prediction tools: For models requiring structural inputs, researchers employ computational tools like ImmuneBuilder2 and IgFold to predict structures from parental sequences .

  • Correlation metrics: Performance evaluation typically uses Spearman and Kendall correlation coefficients to assess how well model predictions align with experimental binding measurements (IC50 or KD values) .

  This multi-faceted approach enables robust comparison between different generative models and facilitates progress toward more accurate antibody design algorithms.

• How do demographic factors influence antibody responses in viral infections?

  Demographic factors significantly impact antibody responses during viral infections, as demonstrated in SARS-CoV-2 studies. A comprehensive analysis of 337 participants from the ISARIC4C cohort revealed distinct patterns based on age, sex, and disease severity:

  • Age and sex interactions: In older males with severe disease (mean age 68 years), peak antibody levels were delayed by 1-2 weeks compared to women, with neutralizing antibody responses delayed even further .

  • Antibody level variations: Males developed higher solid-phase binding antibody responses measured via DABA and IgM binding against Spike, NP, and S1 antigens, though this sex-based difference was not observed for neutralizing antibody responses .

  • Correlation with viral clearance: Higher antibody levels were associated with lower nasal viral RNA, suggesting antibody responses play a role in controlling viral replication and shedding in the upper airway .

  • Disease severity correlation: Anti-RBD responses in Double Antigen Binding Assay (DABA) correlated well with IgM and IgG responses against viral spike, S1, and nucleocapsid protein (NP) antigens, as well as with neutralizing antibody activity and disease severity .

  These findings highlight the importance of considering demographic variables when designing vaccines, interpreting serological data, and developing therapeutic antibodies.

Methodological Considerations

• What strategies can researchers implement to improve antibody validation and research reproducibility?

  To enhance antibody validation and research reproducibility, researchers should implement these strategies:

  • Standardized characterization protocols: Adopt consistent methodologies for antibody validation across different applications (Western blot, immunoprecipitation, immunofluorescence) as demonstrated by the YCharOS platform .

  • Research Resource Identifiers (RRIDs): Use unique identifiers for antibodies to enable traceability and link to validation data in publications .

  • NC3Rs RIVER recommendations: Follow these guidelines which promote best practices in antibody characterization and validation, similar to the widely adopted ARRIVE guidelines for animal research .

  • Independent validation: Verify manufacturer claims through independent testing before using antibodies in critical experiments.

  • Detailed methods reporting: Document complete information about antibody source, catalog number, dilution, incubation conditions, and validation controls in publications.

  • Open science initiatives: Participate in collaborative efforts like the Only Good Antibodies community that share antibody characterization data and validation protocols .

  A roadmap toward improving reproducibility could initially focus on adopting RRIDs linked to characterization data, followed by implementing standardized validation practices across the research ecosystem .

• What techniques are employed to identify and isolate broadly neutralizing antibodies against emerging pathogens?

  Identification and isolation of broadly neutralizing antibodies against emerging pathogens involves sophisticated techniques exemplified by the discovery of SC27, a broadly neutralizing antibody against all SARS-CoV-2 variants and related coronaviruses:

  • Patient sampling strategy: Researchers collect plasma from individuals with hybrid immunity (both infection and vaccination), which often produces more robust and diverse antibody responses .

  • Ig-Seq technology: This advanced sequencing approach enables precise identification of antibody sequences from plasma samples, allowing researchers to obtain exact molecular sequences for potential manufacturing scale-up .

  • Spike protein binding assays: Candidate antibodies are screened for their ability to bind different variants of viral spike proteins, identifying those with broad recognition patterns .

  • Neutralization assays: Functional testing verifies the antibody's ability to prevent viral infection in cellular models across multiple variants .

  • Structural characterization: Determining the antibody-antigen complex structure helps identify conserved epitopes that enable broad neutralization capacity .

  The discovery of broadly neutralizing antibodies like SC27 not only provides potential therapeutic candidates but also reveals conserved viral epitopes that may guide vaccine design strategies for current and future pandemic threats .

• How can researchers effectively compare antibody performance across different experimental platforms?

  Effective comparison of antibody performance across different experimental platforms requires:

  • Standardized controls: Include consistent positive and negative controls across all platforms to establish baseline performance metrics.

  • Cross-platform validation: Systematically evaluate the same antibody across different applications (Western blot, ELISA, immunofluorescence) using standardized protocols as demonstrated by YCharOS .

  • Quantitative metrics: Develop and apply consistent quantitative parameters for sensitivity, specificity, and reproducibility that can be compared across platforms.

  • Reference standards: Use well-characterized reference antibodies or antigen standards to normalize results between different experimental settings.

  • Blind testing: Conduct evaluations where researchers are blinded to antibody identity to reduce confirmation bias.

  • Data sharing: Contribute to repositories of antibody performance data that aggregate results across multiple laboratories and experimental conditions.

  The YCharOS initiative demonstrates this approach by evaluating approximately 1,000 antibodies against ~100 human protein targets using standardized protocols for western blot, immunoprecipitation, and immunofluorescence , creating a valuable resource for antibody selection and experimental design.